Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZILIENT3: zipalertinib plus chemotherapy vs chemotherapy in untreated EGFR exon 20 insertion NSCLC
jRCT2061230058Phase 3Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of zipalertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival (PFS). Started Dec 2023; status: active, not recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061230058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230058.